Does RAD 140 show up on a drug test? It does on an anti-doping test, which looks for the selective androgen receptor modulator (SARM) by name, and not on a routine drugs-of-abuse screen, which was never built to find it. Anti-doping laboratories identify the intact drug and its breakdown products, known as metabolites, by liquid chromatography and mass spectrometry.
Those methods are sensitive enough to pick up RAD140 days after microgram amounts, as excretion studies in volunteers showed. The same methods revealed it in urine samples from a Swedish healthcare laboratory whose own routine screen had reported nothing. That contrast explains why accounts outside the trials describe ordinary workplace panels coming back clean: such panels screen for a fixed set of drugs of abuse, and SARMs are not among them.
The answer therefore depends on what a laboratory was asked to look for, not on the chemistry of RAD 140, which the parent article on RAD 140 science sets out. This article follows the tests: which of them look for RAD140, what the excretion studies, the healthcare samples and the horse studies found, and what a regulator found inside the products.
How anti-doping labs detect RAD140 and its metabolites
Anti-doping laboratories identify RAD140 by chromatography coupled to mass spectrometry, targeting the intact drug and its diagnostic urinary metabolites together. Every published method for SARMs rests on that pairing, liquid chromatography with tandem or high-resolution mass spectrometry (LC-MS/MS or LC-HRMS), whether the sample is urine, hair or a dietary supplement. The chromatographic step separates the SARM RAD140 from everything else in the sample; the mass spectrometer then weighs its fragments. HPLC testing of SARMs for purity rests on the same sequence. Because the approach is so general, the laboratories accredited by the World Anti-Doping Agency (WADA) were able to add new anabolic agents long before any of them reached clinical approval.
Adding a new agent takes one piece of prior work: its fragments must be known. For RAD140, a mass spectrometric study in 2013 established the dissociation pathways and gave the diagnostic product ions, the fragment masses by which a method recognises the molecule, at m/z 223 and 205 under electrospray ionisation. The authors proposed those ions so that RAD140 could go straight into routine gas- and liquid-chromatographic procedures. Later micro-dose excretion work did the same for the metabolites: it described several in human urine for the first time and estimated their concentrations after enzymatic hydrolysis, the step that frees them from the conjugates they are bound to in urine.
Urine is the usual sample, not the only one. Hair or nail testing can complement urinalysis after an adverse analytical finding, the laboratory’s report that a prohibited substance is present, although a negative hair result cannot overrule the urine result. In every case a RAD 140 drug test is a targeted analysis for the drug and its metabolites, not something a laboratory runs by default.
[Figure 1. How anti-doping labs identify RAD140. A doping-control laboratory runs a targeted sequence. Enzymatic hydrolysis frees conjugated metabolites, solid-phase extraction draws the analytes from urine, liquid chromatography separates them, and mass spectrometry identifies RAD140 by product ions at m/z 223 and 205.]
Is there a commercial lab test for RAD140, and which metabolites does it look for?
Outside the published trials, a commercial test for RAD140 is not described as a service offered to the public: the analysis remains the work of anti-doping and specialist forensic toxicology laboratories. Where such a laboratory accepts a sample, it examines urine by liquid chromatography with tandem or high-resolution mass spectrometry after a hydrolysis step that frees the metabolites. The targets are unchanged RAD140, its hydroxylated metabolites, which mostly circulate as glucuronide conjugates, and in some methods its sulfated metabolites. Which of these a laboratory covers varies, and the range widens as the metabolism of the SARM class becomes better known.
[Figure 2. Proposed metabolic pathways of RAD140. The proposed metabolites of RAD140: a hydrolysis product (M5), hydroxylated products (M6, M3), glucuronides (M4, M2) and sulfates (M7, M1). Laboratories target the intact drug together with some of these products, and which ones a method covers varies between laboratories.]
How long RAD140 stays detectable in urine studies
In a transdermal study, RAD140 stayed detectable in urine for up to nine days after 50 micrograms were applied to the lower forearm of five volunteers, and it appeared in all five. At 10 micrograms it appeared in one of five. A study of this kind fixes a detection window, the period after exposure over which a method still finds the drug, by giving a measured amount and collecting urine until the drug vanishes. Windows differ across the class, because the SARMs half-life varies from one compound to the next, and so does the metabolism.
Six further excretion studies, each in five adult men, produced elimination profiles and detection times for six metabolites and the intact drug after oral micro-doses, that is micrograms rather than milligrams. The authors also asked whether the ratios between the metabolites could estimate the amount taken, since those ratios shift as elimination proceeds. A forensic review of adverse analytical findings puts the window for most SARMs at several weeks in urine, longer than these micro-dose experiments covered.
[Figure 3. Urine detection after 50 µg on skin. Five volunteers per compound had 50 µg applied to the forearm. RAD140 was found in their urine for up to 9 days, against 24 days for S-23 and 25 days for the LGD-4033 metabolite M5b. These micro-doses model contamination and give no clearance time after use.]
Both sets of experiments used trace amounts on purpose, to model contamination: the unintended presence of a prohibited substance in a dietary supplement, which has itself produced adverse analytical findings. They show how little exposure a sensitive method can pick up; they do not give a clearance time. How much RAD 140 they found in urine depended on the amount applied and on the sensitivity of the method.
How long can WADA labs detect RAD140, with a study behind it?
No single period is agreed. The measured record is the one set out in the previous section and in the table at the end of this article: the transdermal window, the oral micro-dose profiles, the horse urine and plasma windows. Beyond that record, the window is described as depending on the amount and length of exposure, the route, individual metabolism and the sensitivity of the method. In those accounts WADA-accredited laboratories screen for RAD140 by name, the windows quoted vary widely from one account to another, and that spread is the central uncertainty for testing in and out of competition. The same accounts add that the longer-lived metabolites are targeted as well as the parent drug, so the window lengthens as methods improve.
Will RAD140 still be found months after a cycle ends?
Outside the published trials, RAD140 is described as detectable by anti-doping urine analysis well after exposure ends, because the methods target the parent drug together with its hydroxylated, glucuronidated and sulfated metabolites at very low concentrations. In the controlled studies the parent drug was still present at the last sampling point, so the full window is understood to reach beyond what has been measured. Whether RAD 140 will show on a drug test months after exposure has not been established; hair analysis is regarded as reaching further back than urine. A trace found by such an analysis is a different thing from the result of a routine clinical or workplace panel, which is not designed for SARMs at all.
What anti-doping methods found in healthcare urine samples
Researchers re-analysed urine sent to the Drugs of Abuse Laboratory at Karolinska in Sweden with the screening methods of a WADA-accredited laboratory and identified SARMs in the male samples: testolone among them, with LGD-4033 and ostarine.
[Figure 4. SARMs and steroids in Swedish healthcare urine. Re-analysed with WADA-accredited methods, 20 of 542 male urine samples (4%) from a Swedish healthcare laboratory held SARMs, with RAD140 the second most frequent after LGD-4033. No female sample did. Anabolic steroids were far commoner, in 34% of male and 7% of female samples.]
The same screening read the testosterone/epitestosterone ratio, the urinary marker of administered testosterone, and in many samples that ratio pointed to administration. Such samples risk being reported as negative, because the ratio stood alone, with no other steroid that routine reporting would flag. The samples had been negative only in the sense that the routine panel was not a SARMs drug test: it had never looked for what they held.
Does RAD140 show up on a standard workplace drug test?
Outside the published trials, a standard workplace drug test is described as not detecting RAD140. Routine panels are immunoassay screens, antibody-based tests built for a fixed list of drugs of abuse, and selective androgen receptor modulators are not on that list. RAD140 is neither an approved medicine nor a controlled substance of the kind those panels are designed for, so an ordinary panel has no means of finding it.
The same accounts treat the standard urine drug panel, the fixed screen used for pre-employment and random workplace testing, as the one place where the standing of RAD140 is unsettled: whether that panel, or routine blood work, registers it at all is left an open question, and the same doubt attaches to random and for-cause screening at work. In tested sport the question is a different one, how long a urine sample still holds the compound, and that too is described as unsettled.
The same accounts carry the usual qualification: a laboratory finds RAD140 and its metabolites readily once it looks for them deliberately, by the liquid chromatography and tandem mass spectrometry of anti-doping work. An extended panel that covers anabolic agents can include the SARM. Whether RAD 140 does show on a workplace drug test therefore depends on the scope of the screen the employer requested.
Do DOT or other regulated US work tests include RAD140?
Federally regulated US workplace tests do not include RAD140 or any other selective androgen receptor modulator, and the tests run under Department of Transportation (DOT) rules are no exception. They cover a fixed set of drug classes, none of them anabolic agents:
marijuana
cocaine
amphetamines
opioids
phencyclidine
An employer or a testing programme can commission an expanded or specialised panel. Whether RAD 140 does pop up on a drug test of that kind turns on the panel commissioned: by default RAD140 falls outside the regulated panel, not beyond the reach of detection.
Detecting RAD140 in blood samples
A validated doping-control procedure identifies RAD140 alongside 106 other prohibited compounds in 20 microlitres of serum or plasma: the sample is extracted onto a cellulose card and analysed by liquid chromatography with high-resolution mass spectrometry. The limits of detection, the lowest concentrations the procedure identifies reliably, lay between 0.08 and 7.50 ng/mL across those compounds.
Storage matters as much as sensitivity. RAD-140 stayed stable in serum and plasma for at least three months at −20 and 4 °C, but at 22 °C it was no longer detectable after nine weeks. The temperature a sample was kept at can therefore decide what a blood analysis shows, long before the limit of the method comes into play. Procedures of this kind belong to doping control; the routine blood panels ordered in clinical care work differently.
[Figure 5. Serum sample stability at 22 °C. In spiked serum and plasma kept at 22 °C, RAD140 was undetectable after nine weeks, like the SARM S6. At −20 and 4 °C it stayed stable for at least three months. This is how long a stored sample lasts, not time in the body.]
Can a routine blood test show RAD140 use?
Outside the published trials, a routine blood panel is described as showing RAD-140 testosterone suppression, a marked fall in the serum hormone, while naming no compound at all, and that pattern is widely described as the thing that prompts questions at a clinical review. Liver enzyme, testosterone, oestrogen and thyroid results cannot identify what produced them. The panel registers the hormonal consequence, not the cause, and a clinician reading it sees suppression without a name attached.
In the same accounts the fall shows in blood taken part-way through exposure, and whether a sample taken days after a brief exposure would show anything is left uncertain. What a clinician can read is in the markers that move, the ones that blood work on RAD 140 covers.
Can RAD140 cause a false positive, for example for benzos, estradiol or testosterone?
Outside the published trials, the cases where RAD 140 does pop on a drug test are unexpected readings on screening tests, not identifications of the drug itself. Repeated benzodiazepine positives on one brand of home urine test are described from the start of exposure onward, with a negative result on another brand of the same kind, and one set of laboratory results showed oestradiol but not testosterone.
Set against the analytical literature, those readings are generally held to have no established cause in RAD140. It is a non-steroidal molecule, structurally unlike both the benzodiazepines and the steroid hormones those assays are built to detect, and no such interference appears in the published methods. Immunoassays are nevertheless open to occasional interference from unrelated substances, and their results differ between brands because the antibodies differ. An unexpected screening result therefore counts as presumptive until chromatography and mass spectrometry separate the molecules. A high androgen reading is weighed in the same way against the fall in endogenous testosterone that RAD140 produces, the fall at the centre of RAD 140 vs testosterone: it makes assay interference or another androgen the likelier explanation.
To date, all methods for SARMs identification in various matrices involve liquid chromatography coupled to tandem mass spectrometry or high-resolution mass spectrometry.
The Therapeutic Goods Administration (TGA), the Australian medicines regulator, tested unapproved SARM products and found them significantly under-dosed: they held less of the active substance than the label declared. A container sold as RAD140 may therefore hold less than it states, and it may hold substances the label does not mention. A test result can then come from a substance other than the one named, so the question of RAD140 quality, what a container really holds, bears on how any result is read.
For the same reason we publish batch and purity data for the RAD-140 for sale in our catalogue, supplied for laboratory research, and we document every other compound in the range the same way. Substitution, under-dosing and purity are the three things a test of a product can settle, and they decide what a given container actually holds.
Will RAD140 flag on a standard steroid urine screen?
A standard steroid urine screen does not flag RAD140, because such screens target named anabolic-androgenic steroids and their metabolites, and RAD140, a non-steroidal SARM, is none of them. Outside the published trials, one such screen, ordered by a doctor, returned trenbolone and epitestosterone, a result attributed to a product sold as RAD140; whether RAD140 itself could read as testosterone, trenbolone or another steroid on such a screen is left open in some accounts.
In the analytical literature the drug is commonly described as found only by a targeted method whose list of analytes includes it and its metabolites. A steroid finding in a sample linked to a product sold as RAD140 therefore points to mislabelling or substitution, as analyses of such products have shown more than once; that is the reason the SARMs for sale in our shop carry batch and purity data for each lot.
Can the alcohol carrier in liquid RAD140 cause a positive alcohol test?
Liquid preparations such as RAD 140 drops hold the drug in ethanol, the carrier used in most such preparations, and outside the published trials that carrier is described as a possible cause of a positive alcohol test. The amount of ethanol involved is comparable with other incidental exposures, such as alcohol-based mouthwash or liquid medicines. A breath test registers mouth alcohol only briefly; the sensitive markers of ethanol exposure are ethyl glucuronide and ethyl sulfate in urine. A low breath reading beside near-zero urinary concentrations of those two markers is therefore read as incidental exposure rather than drinking.
What horse and cell studies add on detection
In three retired thoroughbred geldings, intact RAD140 stayed detectable in plasma for up to 13 days after administration, while the parent drug and its sulfate metabolite persisted in hydrolysed urine for up to six days. Plasma held RAD140 about twice as long as urine, so the sample chosen decides what a screen can still find. After 0.3 mg/kg orally for three days the drug also reached the mane hair, from the bloodstream and through sweat or sebum alike, and segmental hair analysis served to trace those two routes rather than to replace urinalysis.
In plasma, RAD140 itself gave the longest detection time of up to 13 days.
Blood screening in animals follows the same logic. A high-throughput assay for equine and bovine blood reached a detection capability (CCβ), the lowest concentration at which a screening method reliably flags a sample, of 5 ng/mL for RAD140. Two cell bioassays measured activity rather than concentration: they confirmed the androgenic effect of RAD-140, weaker in a yeast androgen screen than in prostate carcinoma reporter cells, and raised the question whether the yeast screen could flag SARM administration in urine. None of this animal and cell work transfers directly to humans.
Which testing programmes look for RAD140
Programmes run under the World Anti-Doping Code look for RAD140 in and out of competition, at any time of year, because as a SARM RAD-140 is WADA banned at all times under section S1.2, other anabolic agents. The class joined the Prohibited List in 2008, and adverse analytical findings for various SARMs have followed, rising steadily in the compiled figures for 2015 to 2019 and led by ostarine and ligandrol.
According to the world anti-doping agency (WADA) prohibited list, SARMs are prohibited at all times (i.e. in and out-of-competition) and are listed under the section S1.2 (other anabolic agents).
RAD140, which entered clinical study as vosilasarm, has never received full clinical approval; the class reached sport before any approval, and the laboratories added these agents and their metabolites to their methods without waiting for a licensed product. The methods are sensitive enough that findings have been contested, with contamination argued as the explanation before the Court of Arbitration for Sport. That is what makes the excretion studies and the choice of sample matter to a testing programme as much as to a laboratory.
Does the NCAA test for RAD140?
The National Collegiate Athletic Association (NCAA), the governing body for United States college sport, names RAD140 on its banned substances list among the selective androgen receptor modulators of the anabolic agents class. The list is not exhaustive: it also covers any substance related chemically or pharmacologically to a banned class, and any substance not approved for human therapeutic use. Collegiate samples go to accredited anti-doping laboratories, whose methods cover SARMs and their metabolites.
Are military drug tests more sensitive than other tests?
Outside the published trials, military drug tests are described as no more sensitive than other workplace tests; what sets them apart is the range of substances covered and how often samples are collected. Routine military urinalysis is a two-stage procedure, an immunoassay screen followed by confirmation by mass spectrometry, and its standard panel covers drugs of abuse but not anabolic agents. Whether a military laboratory finds RAD-140 therefore depends on whether a targeted analysis for anabolic agents is ordered. Armed forces regulations list SARMs as prohibited ingredients whatever the routine screen includes.
Do UK workplace or army drug tests screen for RAD140?
Outside the published trials, UK workplace drug tests are described as not screening for RAD140: routine panels are built around controlled drugs of abuse and rest on immunoassay screening, which is not designed for selective androgen receptor modulators. Finding RAD140 takes a dedicated liquid chromatography and mass spectrometry analysis of the anti-doping kind, which a laboratory handling workplace samples would run only on request. The armed forces’ compulsory drug testing programme reaches further, with anabolic-androgenic steroids written into its laboratory requirements, but public statements leave unclear whether that screen extends to SARMs.
Limits of the detection evidence
The human excretion evidence comes from micro-dose studies in groups of five volunteers, so it describes trace exposure and models contamination rather than sustained administration. The hair and plasma findings come from horses, whose metabolism and hair growth differ from ours. None of the article’s sources followed a human sample series after prolonged administration, alone or alongside prescribed testosterone, the case of RAD 140 and TRT, so none fixes a period over which RAD 140 will show up on a drug test after such exposure. The windows above are what sensitive methods find after very small amounts, not the limit of what they can find.
Several matters in this article are known only from descriptions outside the published trials: the benzodiazepine and oestradiol readings on screening tests attributed to RAD140, a positive alcohol test from the ethanol carrier of a liquid preparation, and the hormone changes on routine blood work. No published study among this article’s sources has measured any of them.
RAD140 detection in excretion studies
Study
Subjects
Sample
Exposure
Result
Transdermal study
5 volunteers
Urine
10 µg on the lower forearm
Detected in 1 of 5 volunteers
Transdermal study
5 volunteers
Urine
50 µg on the lower forearm
Detected in all 5, for up to 9 days
Micro-dose excretion studies
6 studies, 5 adult men each
Urine after hydrolysis
Micro-doses (micrograms)
Elimination profiles for 6 metabolites and the intact drug
Detected; reached hair via the bloodstream and via sweat or sebum
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
What did WADA-accredited screening methods find when researchers re-analysed urine samples from a Swedish healthcare laboratory?
SARMs, RAD140 among them, in male samples the routine screen missed ✓
No SARMs, as expected for samples collected outside of sport
Only anabolic steroids, all of them already reported by the routine screen
RAD140 in the female samples but in none of the male samples
Doping-control methods found SARMs, including RAD140, in male healthcare samples, so what a lab finds depends on what it looks for.
In a transdermal study, what happened when 10 micrograms of RAD140 were applied to the lower forearm of five volunteers?
It was detected in the urine of all five volunteers for up to nine days
It was detected in the urine of only one of the five volunteers ✓
It stayed below detection in all five, since skin blocks the compound
It was detected in the urine of three of the five volunteers
Applied topically, 10 micrograms showed up in one volunteer of five, while 50 micrograms showed up in all five for up to nine days.
What did a doping-control study find about RAD140 in stored serum and plasma samples?
It stayed stable for at least a year at any storage temperature tested
It broke down within days unless the samples were frozen at −20 °C
It lasted longer at room temperature than in the refrigerated samples
It kept for months when cold but was gone after nine weeks at 22 °C ✓
RAD140 stayed stable for at least three months at −20 and 4 °C, but at 22 °C it could no longer be detected after nine weeks.
When does the WADA Prohibited List ban SARMs such as RAD140 in sport?
Only in competition, from the days just before an event onward
Only once a licensed medicine containing it has been approved
At all times, in and out of competition, as an anabolic agent ✓
Only out of competition, during the training months of the year
SARMs are prohibited at all times, in and out of competition, under section S1.2, other anabolic agents.
Jeremy Carlier works in the Section of Legal Medicine of the Department of Biomedical Sciences and Public Health at Marche Polytechnic University. Jeremy specialises in doping control analytics and detection.
Lecturer in Analytical Chemistry; Biochemistry course leader
Alexandra Males is a lecturer in analytical chemistry and the biochemistry course leader at Sheffield Hallam University. Alexandra specialises in analytical chemistry, HPLC and chromatography, mass spectrometry, reference standards and metrology, and stability and impurity profiling.
Does RAD 140 show up on a drug test? Which tests look for it
By Jeremy Carlier, PhD · Reviewed by Alexandra Males, PhD
Published · 20 min read
Does RAD 140 show up on a drug test?
Does RAD 140 show up on a drug test? It does on an anti-doping test, which looks for the selective androgen receptor modulator (SARM) by name, and not on a routine drugs-of-abuse screen, which was never built to find it. Anti-doping laboratories identify the intact drug and its breakdown products, known as metabolites, by liquid chromatography and mass spectrometry.
Those methods are sensitive enough to pick up RAD140 days after microgram amounts, as excretion studies in volunteers showed. The same methods revealed it in urine samples from a Swedish healthcare laboratory whose own routine screen had reported nothing. That contrast explains why accounts outside the trials describe ordinary workplace panels coming back clean: such panels screen for a fixed set of drugs of abuse, and SARMs are not among them.
The answer therefore depends on what a laboratory was asked to look for, not on the chemistry of RAD 140, which the parent article on RAD 140 science sets out. This article follows the tests: which of them look for RAD140, what the excretion studies, the healthcare samples and the horse studies found, and what a regulator found inside the products.
How anti-doping labs detect RAD140 and its metabolites
Anti-doping laboratories identify RAD140 by chromatography coupled to mass spectrometry, targeting the intact drug and its diagnostic urinary metabolites together. Every published method for SARMs rests on that pairing, liquid chromatography with tandem or high-resolution mass spectrometry (LC-MS/MS or LC-HRMS), whether the sample is urine, hair or a dietary supplement. The chromatographic step separates the SARM RAD140 from everything else in the sample; the mass spectrometer then weighs its fragments. HPLC testing of SARMs for purity rests on the same sequence. Because the approach is so general, the laboratories accredited by the World Anti-Doping Agency (WADA) were able to add new anabolic agents long before any of them reached clinical approval.
Adding a new agent takes one piece of prior work: its fragments must be known. For RAD140, a mass spectrometric study in 2013 established the dissociation pathways and gave the diagnostic product ions, the fragment masses by which a method recognises the molecule, at m/z 223 and 205 under electrospray ionisation. The authors proposed those ions so that RAD140 could go straight into routine gas- and liquid-chromatographic procedures. Later micro-dose excretion work did the same for the metabolites: it described several in human urine for the first time and estimated their concentrations after enzymatic hydrolysis, the step that frees them from the conjugates they are bound to in urine.
Urine is the usual sample, not the only one. Hair or nail testing can complement urinalysis after an adverse analytical finding, the laboratory’s report that a prohibited substance is present, although a negative hair result cannot overrule the urine result. In every case a RAD 140 drug test is a targeted analysis for the drug and its metabolites, not something a laboratory runs by default.
Is there a commercial lab test for RAD140, and which metabolites does it look for?
Outside the published trials, a commercial test for RAD140 is not described as a service offered to the public: the analysis remains the work of anti-doping and specialist forensic toxicology laboratories. Where such a laboratory accepts a sample, it examines urine by liquid chromatography with tandem or high-resolution mass spectrometry after a hydrolysis step that frees the metabolites. The targets are unchanged RAD140, its hydroxylated metabolites, which mostly circulate as glucuronide conjugates, and in some methods its sulfated metabolites. Which of these a laboratory covers varies, and the range widens as the metabolism of the SARM class becomes better known.
How long RAD140 stays detectable in urine studies
In a transdermal study, RAD140 stayed detectable in urine for up to nine days after 50 micrograms were applied to the lower forearm of five volunteers, and it appeared in all five. At 10 micrograms it appeared in one of five. A study of this kind fixes a detection window, the period after exposure over which a method still finds the drug, by giving a measured amount and collecting urine until the drug vanishes. Windows differ across the class, because the SARMs half-life varies from one compound to the next, and so does the metabolism.
Six further excretion studies, each in five adult men, produced elimination profiles and detection times for six metabolites and the intact drug after oral micro-doses, that is micrograms rather than milligrams. The authors also asked whether the ratios between the metabolites could estimate the amount taken, since those ratios shift as elimination proceeds. A forensic review of adverse analytical findings puts the window for most SARMs at several weeks in urine, longer than these micro-dose experiments covered.
Both sets of experiments used trace amounts on purpose, to model contamination: the unintended presence of a prohibited substance in a dietary supplement, which has itself produced adverse analytical findings. They show how little exposure a sensitive method can pick up; they do not give a clearance time. How much RAD 140 they found in urine depended on the amount applied and on the sensitivity of the method.
How long can WADA labs detect RAD140, with a study behind it?
No single period is agreed. The measured record is the one set out in the previous section and in the table at the end of this article: the transdermal window, the oral micro-dose profiles, the horse urine and plasma windows. Beyond that record, the window is described as depending on the amount and length of exposure, the route, individual metabolism and the sensitivity of the method. In those accounts WADA-accredited laboratories screen for RAD140 by name, the windows quoted vary widely from one account to another, and that spread is the central uncertainty for testing in and out of competition. The same accounts add that the longer-lived metabolites are targeted as well as the parent drug, so the window lengthens as methods improve.
Will RAD140 still be found months after a cycle ends?
Outside the published trials, RAD140 is described as detectable by anti-doping urine analysis well after exposure ends, because the methods target the parent drug together with its hydroxylated, glucuronidated and sulfated metabolites at very low concentrations. In the controlled studies the parent drug was still present at the last sampling point, so the full window is understood to reach beyond what has been measured. Whether RAD 140 will show on a drug test months after exposure has not been established; hair analysis is regarded as reaching further back than urine. A trace found by such an analysis is a different thing from the result of a routine clinical or workplace panel, which is not designed for SARMs at all.
What anti-doping methods found in healthcare urine samples
Researchers re-analysed urine sent to the Drugs of Abuse Laboratory at Karolinska in Sweden with the screening methods of a WADA-accredited laboratory and identified SARMs in the male samples: testolone among them, with LGD-4033 and ostarine.
The same screening read the testosterone/epitestosterone ratio, the urinary marker of administered testosterone, and in many samples that ratio pointed to administration. Such samples risk being reported as negative, because the ratio stood alone, with no other steroid that routine reporting would flag. The samples had been negative only in the sense that the routine panel was not a SARMs drug test: it had never looked for what they held.
Does RAD140 show up on a standard workplace drug test?
Outside the published trials, a standard workplace drug test is described as not detecting RAD140. Routine panels are immunoassay screens, antibody-based tests built for a fixed list of drugs of abuse, and selective androgen receptor modulators are not on that list. RAD140 is neither an approved medicine nor a controlled substance of the kind those panels are designed for, so an ordinary panel has no means of finding it.
The same accounts treat the standard urine drug panel, the fixed screen used for pre-employment and random workplace testing, as the one place where the standing of RAD140 is unsettled: whether that panel, or routine blood work, registers it at all is left an open question, and the same doubt attaches to random and for-cause screening at work. In tested sport the question is a different one, how long a urine sample still holds the compound, and that too is described as unsettled.
The same accounts carry the usual qualification: a laboratory finds RAD140 and its metabolites readily once it looks for them deliberately, by the liquid chromatography and tandem mass spectrometry of anti-doping work. An extended panel that covers anabolic agents can include the SARM. Whether RAD 140 does show on a workplace drug test therefore depends on the scope of the screen the employer requested.
Do DOT or other regulated US work tests include RAD140?
Federally regulated US workplace tests do not include RAD140 or any other selective androgen receptor modulator, and the tests run under Department of Transportation (DOT) rules are no exception. They cover a fixed set of drug classes, none of them anabolic agents:
An employer or a testing programme can commission an expanded or specialised panel. Whether RAD 140 does pop up on a drug test of that kind turns on the panel commissioned: by default RAD140 falls outside the regulated panel, not beyond the reach of detection.
Detecting RAD140 in blood samples
A validated doping-control procedure identifies RAD140 alongside 106 other prohibited compounds in 20 microlitres of serum or plasma: the sample is extracted onto a cellulose card and analysed by liquid chromatography with high-resolution mass spectrometry. The limits of detection, the lowest concentrations the procedure identifies reliably, lay between 0.08 and 7.50 ng/mL across those compounds.
Storage matters as much as sensitivity. RAD-140 stayed stable in serum and plasma for at least three months at −20 and 4 °C, but at 22 °C it was no longer detectable after nine weeks. The temperature a sample was kept at can therefore decide what a blood analysis shows, long before the limit of the method comes into play. Procedures of this kind belong to doping control; the routine blood panels ordered in clinical care work differently.
Can a routine blood test show RAD140 use?
Outside the published trials, a routine blood panel is described as showing RAD-140 testosterone suppression, a marked fall in the serum hormone, while naming no compound at all, and that pattern is widely described as the thing that prompts questions at a clinical review. Liver enzyme, testosterone, oestrogen and thyroid results cannot identify what produced them. The panel registers the hormonal consequence, not the cause, and a clinician reading it sees suppression without a name attached.
In the same accounts the fall shows in blood taken part-way through exposure, and whether a sample taken days after a brief exposure would show anything is left uncertain. What a clinician can read is in the markers that move, the ones that blood work on RAD 140 covers.
Can RAD140 cause a false positive, for example for benzos, estradiol or testosterone?
Outside the published trials, the cases where RAD 140 does pop on a drug test are unexpected readings on screening tests, not identifications of the drug itself. Repeated benzodiazepine positives on one brand of home urine test are described from the start of exposure onward, with a negative result on another brand of the same kind, and one set of laboratory results showed oestradiol but not testosterone.
Set against the analytical literature, those readings are generally held to have no established cause in RAD140. It is a non-steroidal molecule, structurally unlike both the benzodiazepines and the steroid hormones those assays are built to detect, and no such interference appears in the published methods. Immunoassays are nevertheless open to occasional interference from unrelated substances, and their results differ between brands because the antibodies differ. An unexpected screening result therefore counts as presumptive until chromatography and mass spectrometry separate the molecules. A high androgen reading is weighed in the same way against the fall in endogenous testosterone that RAD140 produces, the fall at the centre of RAD 140 vs testosterone: it makes assay interference or another androgen the likelier explanation.
What regulator testing found in SARM products
The Therapeutic Goods Administration (TGA), the Australian medicines regulator, tested unapproved SARM products and found them significantly under-dosed: they held less of the active substance than the label declared. A container sold as RAD140 may therefore hold less than it states, and it may hold substances the label does not mention. A test result can then come from a substance other than the one named, so the question of RAD140 quality, what a container really holds, bears on how any result is read.
For the same reason we publish batch and purity data for the RAD-140 for sale in our catalogue, supplied for laboratory research, and we document every other compound in the range the same way. Substitution, under-dosing and purity are the three things a test of a product can settle, and they decide what a given container actually holds.
Will RAD140 flag on a standard steroid urine screen?
A standard steroid urine screen does not flag RAD140, because such screens target named anabolic-androgenic steroids and their metabolites, and RAD140, a non-steroidal SARM, is none of them. Outside the published trials, one such screen, ordered by a doctor, returned trenbolone and epitestosterone, a result attributed to a product sold as RAD140; whether RAD140 itself could read as testosterone, trenbolone or another steroid on such a screen is left open in some accounts.
In the analytical literature the drug is commonly described as found only by a targeted method whose list of analytes includes it and its metabolites. A steroid finding in a sample linked to a product sold as RAD140 therefore points to mislabelling or substitution, as analyses of such products have shown more than once; that is the reason the SARMs for sale in our shop carry batch and purity data for each lot.
Can the alcohol carrier in liquid RAD140 cause a positive alcohol test?
Liquid preparations such as RAD 140 drops hold the drug in ethanol, the carrier used in most such preparations, and outside the published trials that carrier is described as a possible cause of a positive alcohol test. The amount of ethanol involved is comparable with other incidental exposures, such as alcohol-based mouthwash or liquid medicines. A breath test registers mouth alcohol only briefly; the sensitive markers of ethanol exposure are ethyl glucuronide and ethyl sulfate in urine. A low breath reading beside near-zero urinary concentrations of those two markers is therefore read as incidental exposure rather than drinking.
What horse and cell studies add on detection
In three retired thoroughbred geldings, intact RAD140 stayed detectable in plasma for up to 13 days after administration, while the parent drug and its sulfate metabolite persisted in hydrolysed urine for up to six days. Plasma held RAD140 about twice as long as urine, so the sample chosen decides what a screen can still find. After 0.3 mg/kg orally for three days the drug also reached the mane hair, from the bloodstream and through sweat or sebum alike, and segmental hair analysis served to trace those two routes rather than to replace urinalysis.
Blood screening in animals follows the same logic. A high-throughput assay for equine and bovine blood reached a detection capability (CCβ), the lowest concentration at which a screening method reliably flags a sample, of 5 ng/mL for RAD140. Two cell bioassays measured activity rather than concentration: they confirmed the androgenic effect of RAD-140, weaker in a yeast androgen screen than in prostate carcinoma reporter cells, and raised the question whether the yeast screen could flag SARM administration in urine. None of this animal and cell work transfers directly to humans.
Which testing programmes look for RAD140
Programmes run under the World Anti-Doping Code look for RAD140 in and out of competition, at any time of year, because as a SARM RAD-140 is WADA banned at all times under section S1.2, other anabolic agents. The class joined the Prohibited List in 2008, and adverse analytical findings for various SARMs have followed, rising steadily in the compiled figures for 2015 to 2019 and led by ostarine and ligandrol.
RAD140, which entered clinical study as vosilasarm, has never received full clinical approval; the class reached sport before any approval, and the laboratories added these agents and their metabolites to their methods without waiting for a licensed product. The methods are sensitive enough that findings have been contested, with contamination argued as the explanation before the Court of Arbitration for Sport. That is what makes the excretion studies and the choice of sample matter to a testing programme as much as to a laboratory.
Does the NCAA test for RAD140?
The National Collegiate Athletic Association (NCAA), the governing body for United States college sport, names RAD140 on its banned substances list among the selective androgen receptor modulators of the anabolic agents class. The list is not exhaustive: it also covers any substance related chemically or pharmacologically to a banned class, and any substance not approved for human therapeutic use. Collegiate samples go to accredited anti-doping laboratories, whose methods cover SARMs and their metabolites.
Are military drug tests more sensitive than other tests?
Outside the published trials, military drug tests are described as no more sensitive than other workplace tests; what sets them apart is the range of substances covered and how often samples are collected. Routine military urinalysis is a two-stage procedure, an immunoassay screen followed by confirmation by mass spectrometry, and its standard panel covers drugs of abuse but not anabolic agents. Whether a military laboratory finds RAD-140 therefore depends on whether a targeted analysis for anabolic agents is ordered. Armed forces regulations list SARMs as prohibited ingredients whatever the routine screen includes.
Do UK workplace or army drug tests screen for RAD140?
Outside the published trials, UK workplace drug tests are described as not screening for RAD140: routine panels are built around controlled drugs of abuse and rest on immunoassay screening, which is not designed for selective androgen receptor modulators. Finding RAD140 takes a dedicated liquid chromatography and mass spectrometry analysis of the anti-doping kind, which a laboratory handling workplace samples would run only on request. The armed forces’ compulsory drug testing programme reaches further, with anabolic-androgenic steroids written into its laboratory requirements, but public statements leave unclear whether that screen extends to SARMs.
Limits of the detection evidence
The human excretion evidence comes from micro-dose studies in groups of five volunteers, so it describes trace exposure and models contamination rather than sustained administration. The hair and plasma findings come from horses, whose metabolism and hair growth differ from ours. None of the article’s sources followed a human sample series after prolonged administration, alone or alongside prescribed testosterone, the case of RAD 140 and TRT, so none fixes a period over which RAD 140 will show up on a drug test after such exposure. The windows above are what sensitive methods find after very small amounts, not the limit of what they can find.
Several matters in this article are known only from descriptions outside the published trials: the benzodiazepine and oestradiol readings on screening tests attributed to RAD140, a positive alcohol test from the ethanol carrier of a liquid preparation, and the hormone changes on routine blood work. No published study among this article’s sources has measured any of them.
RAD140 detection in excretion studies
Check what you remember
4 questions on this article; the right answer is marked.
Doping-control methods found SARMs, including RAD140, in male healthcare samples, so what a lab finds depends on what it looks for.
Applied topically, 10 micrograms showed up in one volunteer of five, while 50 micrograms showed up in all five for up to nine days.
RAD140 stayed stable for at least three months at −20 and 4 °C, but at 22 °C it could no longer be detected after nine weeks.
SARMs are prohibited at all times, in and out of competition, under section S1.2, other anabolic agents.
Jeremy Carlier, PhD · Marche Polytechnic University
Jeremy Carlier works in the Section of Legal Medicine of the Department of Biomedical Sciences and Public Health at Marche Polytechnic University. Jeremy specialises in doping control analytics and detection.
Alexandra Males, PhD · Sheffield Hallam University · Last reviewed
Lecturer in Analytical Chemistry; Biochemistry course leader
Alexandra Males is a lecturer in analytical chemistry and the biochemistry course leader at Sheffield Hallam University. Alexandra specialises in analytical chemistry, HPLC and chromatography, mass spectrometry, reference standards and metrology, and stability and impurity profiling.